In one paragraphArticle in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Sarka JanusovaLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-0111-497X Darina PaprckovaLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-0151-4797 Juraj MichalikLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-8479-0991 Valeria UleriLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-5040-5995 Ales DrobekLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Eva SalyovaLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-7947-5778 Louise ChorfiLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Ales NeuwirthLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0003-4668-4316 Arina AndreyevaLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0009-0005-6061-3428 Jan ProchazkaCzech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0003-4675-8995 Radislav SedlacekCzech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Peter DraberLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-8658-4614 Ondrej StepanekLaboratory of Adaptive Immunity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. ondrej.stepanek@img.cas.cz.
Funding
EC | ERC | HORIZON EUROPE European Research Council (ERC) 802878European Molecular Biology Organization (EMBO) IG 4420European Union - Next Generation EU LX22NPO5103Grantová Agentura České Republiky (GAČR) 22-18046SGrantová Agentura, Univerzita Karlova (GA UK) 274323Grantová Agentura, Univerzita Karlova (GA UK) 984120Ministerstvo Školství, Mládeže a Tělovýchovy (MŠMT) LM2023036Ministerstvo Školství, Mládeže a Tělovýchovy (MŠMT) LM2023050Ministerstvo Školství, Mládeže a Tělovýchovy (MŠMT) OP RDI BIOCEV CZ.1.05/1.1.00/02.0109Ministerstvo Školství, Mládeže a Tělovýchovy (MŠMT) OP RDI CZ.1.05/2.1.00/19.0395Ministerstvo Školství, Mládeže a Tělovýchovy (MŠMT) RVO - 68378050-KAV-NPUIUniverzita Karlova v Praze (UK) PRIMUS/20/MED/003Ústav molekulární genetiky, AVČR core funding RVO 68378050
6 · The paper itselfAbstract
T cells are pivotal in the adaptive immune defense, necessitating a delicate balance between robust response against infections and self-tolerance. Their activation involves intricate cross-talk among signaling pathways triggered by the T-cell antigen receptors (TCR) and co-stimulatory or inhibitory receptors. The molecular regulation of these complex signaling networks is still incompletely understood. Here, we identify the adaptor protein ABIN1 as a component of the signaling complexes of GITR and OX40 co-stimulation receptors. T cells lacking ABIN1 are hyper-responsive ex vivo, exhibit enhanced responses to cognate infections, and superior ability to induce experimental autoimmune diabetes in mice. ABIN1 negatively regulates p38 kinase activation and late NF-κB target genes. P38 is at least partially responsible for the upregulation of the key effector proteins IFNG and GZMB in ABIN1-deficient T cells after TCR stimulation. Our findings reveal the intricate role of ABIN1 in T-cell regulation.
Indexed as
Adaptor Proteins, Signal TransducingSignal TransductionT-Lymphocytes, CytotoxicAnimalsDiabetes Mellitus, Type 1Glucocorticoid-Induced TNFR-Related ProteinHumansInterferon-gammaLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutNF-kappa Bp38 Mitogen-Activated Protein KinasesReceptors, Antigen, T-CellReceptors, OX40Adaptor Proteins, Signal TransducingGlucocorticoid-Induced TNFR-Related ProteinInterferon-gammaNF-kappa Bp38 Mitogen-Activated Protein KinasesReceptors, Antigen, T-CellReceptors, OX40Tnfrsf18 protein, mouseABIN1Antigen ReceptorCo-stimulationp38T Cells
Identifiers
PMID38877170
PMCPMC11315980
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390